Mutation of PFN1 Gene in an Early Onset, Polyostotic Paget-like Disease.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 08 2020
Historique:
received: 24 03 2020
accepted: 05 05 2020
pubmed: 12 5 2020
medline: 9 2 2021
entrez: 12 5 2020
Statut: ppublish

Résumé

Paget disease of bone (PDB) is a metabolic bone disease whose genetic cause remains unknown in up to 50% of familial patients. Our aim was to investigate the underlying genetic defect in a large pedigree with a severe, early onset, autosomal dominant form of PDB across 3 generations. Whole exome sequencing was performed in affected and unaffected family members, and then mutation screening was replicated in a sample of PDB patients with early-onset, polyostotic PDB. We identified a frameshift D107Rfs*3 mutation in PFN1 (encoding for profilin 1, a highly conserved regulator of actin-polymerization and cell motility) causing the truncation of the C-terminal part of the protein. The mutation was also detected in a 17-year-old asymptomatic family member who upon biochemical and radiological analyses was indeed found to be affected. Sequencing of the entire PFN1 coding region in unrelated PDB patients identified the same mutation in 1 patient. All mutation carriers had a reduced response to bisphosphonates, requiring multiple zoledronate infusions to control bone pain and achieve biochemical remission over a long term. In vitro osteoclastogenesis in peripheral blood mononuclear cells (PBMCs) from mutation carriers showed a higher number of osteoclasts with PDB-like features. A similar phenotype was observed upon PFN1 silencing in murine bone marrow-derived monocytes, suggesting that the frameshift PFN1 mutation confers a loss of function in profilin 1 activity that induces PDB-like features in the osteoclasts, likely due to enhanced cell motility and actin ring formation. Our findings indicate that PFN1 mutation causes an early onset, polyostotic PDB-like disorder.

Identifiants

pubmed: 32392277
pii: 5835857
doi: 10.1210/clinem/dgaa252
pii:
doi:

Substances chimiques

PFN1 protein, human 0
Pfn1 protein, mouse 0
Profilins 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Daniela Merlotti (D)

Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.

Maria Materozzi (M)

Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.
Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

Simone Bianciardi (S)

Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.

Vito Guarnieri (V)

Medical Genetics Service, IRCCS "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (FG), Italy.

Domenico Rendina (D)

Department of Clinical and Surgical Sciences, Federico II University Medical School, Naples, Italy.

Luca Volterrani (L)

Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.

Cristiana Bellan (C)

Department of Medical Biotechnologies, University of Siena, Italy.

Christian Mingiano (C)

Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.

Tommaso Picchioni (T)

Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.

Alessandro Frosali (A)

Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.

Ugo Orfanelli (U)

Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

Simone Cenci (S)

Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

Luigi Gennari (L)

Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH